[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590787":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":36,"locations":24,"responsibleParty":41,"collaborators":43,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":24,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":69,"whyStopped":24,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":24},{"fullName":5,"class":6},"National Cancer Center, Korea","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"low TSH group","EXPERIMENTAL","0.3 ≤ target TSH \\\u003C2.0mIU\u002FL",[13],"Drug: Levothyroxin",{"label":15,"type":10,"description":16,"interventionNames":17},"high TSH group","2.0 ≤ target TSH \\\u003C8.0mIU\u002FL",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Levothyroxin","During the five-year study intervention period, thyroid hormone (oral administration) supplementary doses are determined according to a dose-adjustment protocol established for the group's target TSH range.",[15,9],null,[26,30,33],{"name":27,"affiliation":28,"role":29},"Eun Kyung Lee","National Cancer Center","PRINCIPAL_INVESTIGATOR",{"name":31,"affiliation":32,"role":29},"Young Joo Park","Seoul National University Hospital",{"name":34,"affiliation":35,"role":29},"Minjoo Kim","Seoul National University Bundang Hospital",[37],{"name":27,"role":38,"phone":39,"phoneExt":24,"email":40},"CONTACT","+82-31-920-1743","eklee@ncc.re.kr",{"type":42,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[44,46],{"name":32,"class":45},"OTHER",{"name":35,"class":45},"100590787","necessity-of-tsh-suppression-therapy-in-active-surveillance-for-thyroid-cancer-patients-100590787",false,"NCT06971965","Necessity of TSH Suppression Therapy in Active Surveillance for Thyroid Cancer Patients.","MAeSTro-TSH","Inclusion Criteria:\n\n* Thyroid nodule of 1.0 cm or less confirmed as Bethesda category V (suspicious for PTC) or VI (PTC) based on cytopathological examination, or Bethesda category III (atypia of undetermined significance) with a confirmed BRAF V600E mutation.\n* Patients with no evidence of distant metastasis, cervical lymph node metastasis, recurrent laryngeal nerve invasion, or tracheal invasion. Additionally, no evidence of extrathyroidal extension (ETE) should be present, and the tumor must not belong to high-risk subtypes of PTC (e.g., diffuse sclerosing, columnar cell, or solid subtype).\n* Non-pregnant women of childbearing potential (confirmed by medical history taking)\n\nExclusion Criteria:\n\n* Hyperthyroidism\n* If the investigator determines that you are not suitable for clinical research participation considering the following comorbidities:\n\n  * Myocardial infarction or cerebrovascular accident within the last three months.\n  * Diseases with limited life expectancy or potentially impairing the patient's ability to comply with at least five years of treatment or follow-up.","ALL","19 Years","79 Years",{"count":58,"type":59},578,"ESTIMATED","INTERVENTIONAL",[62],"NA","This study is a multicenter randomized controlled trial conducted in Korea. A parallel, two-group randomized design will be with thyroid stimulating hormone suppression therapy group(low TSH group; intervention) is different from the wIthout thyroid stimulating hormone (TSH) suppression therapy group(high TSH group; control).",[65,66],"Thyroid Cancer","Papillary Thyroid Carcinoma",[68],"Active Surveillance","NOT_YET_RECRUITING","2025-05-07",{"date":72,"type":73},"2025-05-14","ACTUAL",{"date":75,"type":59},"2025-06-02",{"date":77,"type":59},"2032-12-31",{"name":5,"class":6}]